As­traZeneca her­alds Tagris­so's OS lead over old TKIs in lung can­cer niche

BARCELONA — As­traZeneca is draw­ing the cur­tains on just how much longer Tagris­so can help non-small cell lung can­cer pa­tients live com­pared to first-gen­er­a­tion ty­ro­sine …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.